Enzon Pharmaceuticals, Inc.
ENZN
$0.06
$0.005.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 318.00K | 229.00K | 314.00K | 1.00M | 325.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 318.00K | 229.00K | 314.00K | 1.00M | 325.00K |
| Operating Income | -318.00K | -229.00K | -314.00K | -1.00M | -325.00K |
| Income Before Tax | -1.05M | -808.00K | -1.03M | -505.00K | 221.00K |
| Income Tax Expenses | 26.00K | 16.00K | -42.00K | 19.00K | 293.00K |
| Earnings from Continuing Operations | -1.07M | -824.00K | -990.00K | -524.00K | -72.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.07M | -824.00K | -990.00K | -524.00K | -72.00K |
| EBIT | -318.00K | -229.00K | -314.00K | -1.00M | -325.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
| Average Diluted Shares Outstanding | 74.22M | 74.22M | 74.22M | 74.22M | 74.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | 0.00% | 0.00% | -243.32% | 0.00% |